NovMetaPharma Co Ltd
229500
Company Profile
Business description
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer’s disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.
Contact
727 13, Gangnam-gu, Seoul eonju layer
Seoul
KORT: +82 25381893
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.80 | 12.90 | 0.15% |
| CAC 40 | 7,789.46 | 1.36 | 0.02% |
| DAX 40 | 23,972.81 | 65.38 | -0.27% |
| Dow JONES (US) | 42,101.57 | 2.87 | 0.01% |
| FTSE 100 | 8,726.32 | 0.31 | 0.00% |
| HKSE | 23,573.38 | 315.07 | 1.35% |
| NASDAQ | 19,244.89 | 143.95 | 0.75% |
| Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
| NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
| S&P 500 | 5,913.02 | 24.47 | 0.42% |
| S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
| SSE Composite Index | 3,363.45 | 23.51 | 0.70% |